Want to see RMTI full AI Analyst Report?
Top Page
Rockwell Med
(NASDAQ:RMTI)
Select Model
Select Model
Rating:57Neutral
Price Target:
$7.00
▼(-11.84% Downside)
Action:Reiterated
Date:10/07/26
RMTI scores moderately due to improving fundamentals and a positive earnings-call outlook (reiterated guidance, margin expansion, positive operating cash flow, and strong liquidity), partially offset by still-weak profitability in the financial statements and mixed-to-weak technical positioning with the stock trading below key moving averages. Valuation remains challenging because losses drive a negative P/E and there is no dividend support.
Positive Factors
Customer Diversification
Serving about 300 customers, including all five major U.S. dialysis providers and 30+ international markets, broadens commercial reach. New and renewed agreements with annual pricing provisions can improve revenue visibility and reduce reliance on any single customer relationship.
Negative Factors
Persistent Losses
TTM operating and EBITDA margins remain negative and the company reported a $1.2M Q2 net loss, despite year-over-year improvement. Continued GAAP losses indicate the business has not yet converted operational progress into dependable earnings, limiting internally generated capital for growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Customer Diversification
Serving about 300 customers, including all five major U.S. dialysis providers and 30+ international markets, broadens commercial reach. New and renewed agreements with annual pricing provisions can improve revenue visibility and reduce reliance on any single customer relationship.
Read all positive factors
Rockwell Med (RMTI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.65M
Dividend YieldN/A
Average Volume (3M)25.15K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue Growth-21.12%
EPS Growth-109.07%
CountryUS
Employees157
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.39
Shares Outstanding4,030,465
10 Day Avg. Volume34,772
30 Day Avg. Volume25,149
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.81
Price to Sales (P/S)0.43
P/FCF Ratio-24.98
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue0.16
Enterprise Value/Gross Profit0.89
Enterprise Value/Ebitda-5.88
Forecast
1Y Price Target
$20.00Price Target Upside151.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.94
Revenue Forecast (FY)$72.49M
Rockwell Med Business Overview & Revenue Model
Company Description
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing ir...
How the Company Makes Money
Rockwell Medical generates revenue primarily by selling products used in hemodialysis to dialysis providers and other healthcare customers. Its revenue model is product-sales driven: (1) sales of dialysis-related pharmaceutical products/therapies ...
Rockwell Med Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 12, 2026
Earnings Call Sentiment Positive
The call emphasized clear operational and financial progress: double-digit quarterly revenue growth, a 30% increase in quarterly gross profit, expanding gross margins (18% in Q2), positive operating cash flow (~$2.1M in Q2), strengthened liquidity ($24.8M), new customer agreements and capacity-adding automation. Offsetting these positives are that the company remains GAAP-loss-making (Q2 net loss $1.2M), adjusted EBITDA for the quarter remained negative $200K, six-month revenue was flat due to a prior-year purchasing distortion, and an early-stage device initiative and the recent reverse split present execution and perception risks. On balance, the improving top-line, margin expansion, positive cash generation, and reiterated guidance indicate momentum that materially outweighs the remaining short-term profitability and execution risks.Positive Updates
Quarterly Revenue Growth
Net sales for Q2 2026 were $17.8M, an 11% increase year-over-year from $16.1M, and represented sequential growth versus Q1 2026 driven by new Western U.S. customers and increased purchases from existing customers.
Negative Updates
Continued Net Loss
Net loss for Q2 2026 was $1.2M (improved from $1.5M in Q2 2025 and $1.6M in Q1 2026), and first half net loss was $2.8M versus $3.0M in the prior year — company remains unprofitable on a GAAP basis despite improvements.
Read all updates
Q2-2026 Updates
Positive
Negative
Quarterly Revenue Growth
Net sales for Q2 2026 were $17.8M, an 11% increase year-over-year from $16.1M, and represented sequential growth versus Q1 2026 driven by new Western U.S. customers and increased purchases from existing customers.
Read all positive updates
Company Guidance
Rockwell reiterated full‑year 2026 guidance of net sales $70–75M, gross margin 18–22%, adjusted EBITDA $1–2M and positive operating cash flow, citing Q2 traction including net sales of $17.8M (up 11% YoY; H1 $35.1M), Q2 gross profit $3.2M (+30% YoY) and Q2 gross margin of 18% (vs 16% Q2’25 and 17% Q1’26), Q2 net loss of $1.2M (H1 net loss $2.8M vs $3.0M prior year), Q2 adjusted EBITDA of negative $0.2M (H1 adjusted EBITDA improved $0.2M year‑over‑year), approximately $2.1M cash from operations in Q2 and a quarter‑end cash balance of $24.8M; management reiterated longer‑term targets of >$100M annual sales and ~30% gross margin by 2029.Rockwell Med Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
68
Positive
Cash Flow
61
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 69.39M | 69.26M | 101.49M | 83.61M | 72.81M | 61.93M |
| Gross Profit | 12.29M | 11.70M | 17.48M | 8.70M | 4.08M | -2.42M |
| EBITDA | -1.86M | -2.00M | 2.95M | -4.69M | -16.17M | -27.80M |
| Net Income | -5.08M | -5.31M | -480.00K | -8.44M | -18.68M | -32.67M |
Balance Sheet | ||||||
| Total Assets | 56.53M | 57.15M | 59.21M | 52.17M | 46.63M | 48.57M |
| Cash, Cash Equivalents and Short-Term Investments | 24.80M | 25.00M | 21.60M | 10.94M | 21.49M | 22.44M |
| Total Debt | 13.93M | 12.47M | 13.54M | 13.44M | 16.36M | 28.89M |
| Total Liabilities | 21.44M | 20.16M | 26.62M | 30.88M | 32.53M | 46.04M |
| Stockholders Equity | 35.09M | 36.98M | 32.59M | 21.29M | 14.11M | 2.54M |
Cash Flow | ||||||
| Free Cash Flow | 1.54M | -1.20M | 3.19M | -9.70M | -17.21M | -34.06M |
| Operating Cash Flow | 2.90M | -659.00K | 4.20M | -9.41M | -16.93M | -33.53M |
| Investing Cash Flow | -9.05M | -8.54M | -4.87M | -3.04M | -2.40M | 311.00K |
| Financing Cash Flow | 4.19M | 4.25M | 7.35M | 11.34M | 16.15M | -2.18M |
Rockwell Med Technical Analysis
Negative
7.94
Price Trends
7.93
Negative
7.22
Negative
8.27
Negative
Market Momentum
-0.30
Positive
35.10
Neutral
8.92
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RMTI, the sentiment is Negative. The current price of 7.94 is above the 20-day moving average (MA) of 7.70, above the 50-day MA of 7.93, and below the 200-day MA of 8.27, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 35.10 is Neutral, neither overbought nor oversold. The STOCH value of 8.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RMTI.
Rockwell Med Risk Analysis
Rockwell Med disclosed 35 risk factors in its most recent earnings report. Rockwell Med reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rockwell Med Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.46B | 110.02 | 40.13% | ― | 81.49% | ― | |
68 Neutral | $1.45B | 103.38 | 2.13% | ― | 5.71% | ― | |
68 Neutral | $1.63B | 14.73 | 19.19% | ― | 30.90% | ― | |
57 Neutral | $27.65M | -4.94 | -14.03% | ― | -21.12% | -109.07% | |
52 Neutral | $116.12M | -1.10 | -24.23% | ― | 6.50% | -613.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $74.17M | -6.93 | -47.10% | 28.00% | -25.68% | -244.92% |
* Healthcare Sector Average
RMTI
Rockwell Med
6.86
-4.34
-38.75%
PCRX
Pacira Pharmaceuticals
36.40
15.04
70.41%
ANIP
ANI Pharmaceuticals
71.17
-22.12
-23.71%
CPIX
Cumberland Pharmaceuticals
4.95
2.39
93.51%
ORGO
Organogenesis Holdings
0.90
-3.29
-78.47%
ETON
Eton Pharmaceuticals
51.16
32.56
175.05%
Rockwell Med Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Rockwell Medical Releases Updated Investor Corporate Presentation
Neutral
Aug 13, 2026
On August 13, 2026, Rockwell Medical, Inc. made available an updated corporate presentation to investors and other stakeholders, signaling a refreshed package of company information and strategy materials. The presentation was furnished as a suppl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.